Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H27FO5 |
Molecular Weight | 378.4345 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](O)[C@H]3[C@@H](C[C@H](F)C4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
InChI
InChIKey=MYYIMZRZXIQBGI-HVIRSNARSA-N
InChI=1S/C21H27FO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7,12-13,15-16,18,23,25,27H,4,6,8-10H2,1-2H3/t12-,13-,15-,16-,18+,19-,20-,21-/m0/s1
Molecular Formula | C21H27FO5 |
Molecular Weight | 378.4345 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/13892052Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/5818823 | http://www.tabletwise.com/us/alphadrol-tablet
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13892052
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/5818823 | http://www.tabletwise.com/us/alphadrol-tablet
Fluprednisolone is glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated (hypersensitivity dermatoses, contact dermatitis, pemphigus, pemphigoid, lupus erythematosus, neoplasia etc), except adrenal deficiency states.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/92477 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ALPHADROL Approved UseUnknown Launch Date1978 |
|||
Primary | ALPHADROL Approved UseUnknown Launch Date1978 |
|||
Primary | ALPHADROL Approved UseUnknown Launch Date1978 |
Doses
Dose | Population | Adverse events |
---|---|---|
5.25 mg/m2 1 times / day multiple, oral Highest studied dose Dose: 5.25 mg/m2, 1 times / day Route: oral Route: multiple Dose: 5.25 mg/m2, 1 times / day Sources: |
unhealthy, 0-16 |
|
5.25 mg 1 times / day multiple, oral Dose: 5.25 mg, 1 times / day Route: oral Route: multiple Dose: 5.25 mg, 1 times / day Sources: |
unhealthy, children Health Status: unhealthy Age Group: children Sex: M+F Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of exogenous glucocorticoid injection on preweaning growth performance of neonatal pigs under commercial conditions. | 2004 Apr |
|
Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion. | 2010 Aug |
|
Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. | 2010 Jun |
|
Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13892052
A dose of 3 mg per kilogram in dogs for a period of two weeks produced no toxic effects.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5818823
Lymphosarcoma P1798 cells was treated with 9FP (Fluprednisolone). Ribonuclease activity of the cells was measured after incubation with 0.1 mkg/ml 9FP (Fluprednisolone) for various time periods (from 6 to 48 h). Cells also develop increased acid ribonuclease activity after incubation with 9FP (Fluprednisolone) in vitro.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:05 GMT 2025
by
admin
on
Mon Mar 31 17:49:05 GMT 2025
|
Record UNII |
9H05937G3X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D005477
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
3335
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
FLUPREDNISOLONE
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
DTXSID5046067
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
SUB07736MIG
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
53-34-9
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
C65730
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
m5493
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
1216
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
5876
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
1352
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
9H05937G3X
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
100000080742
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
47439
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
DB09378
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
200-170-8
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200774
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | |||
|
4497
Created by
admin on Mon Mar 31 17:49:05 GMT 2025 , Edited by admin on Mon Mar 31 17:49:05 GMT 2025
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |